ProShares Ultra NASDAQ Biotechnology
BIB
BIB
36 hedge funds and large institutions have $18.2M invested in ProShares Ultra NASDAQ Biotechnology in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
20% more funds holding
Funds holding: 30 → 36 (+6)
0.85% less ownership
Funds ownership: 7.55% → 6.7% (-0.85%)
Holders
36
Holding in Top 10
–
Calls
$14.5M
Puts
$7.35M
Top Buyers
| 1 | +$1.06M | |
| 2 | +$576K | |
| 3 | +$514K | |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$436K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$243K |
Top Sellers
| 1 | -$1.37M | |
| 2 | -$670K | |
| 3 | -$502K | |
| 4 |
UMC
United Maritime Capital
New York
|
-$197K |
| 5 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$137K |